查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571766

人类胚胎干细胞市场规模、份额、趋势分析报告：按应用、地区、细分市场预测，2024-2030

Human Embryonic Stem Cells Market Size, Share & Trends Analysis Report By Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

人类胚胎干细胞市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球人类胚胎干细胞市场规模预计将达到40.8亿美元，2024年至2030年复合年增长率为10.5%。

hESCs 技术由于其宿主-移植物组织相容性高，往往可用于人体组织工程。

发育潜力的维持，即所有三个生殖细胞层对衍生物的贡献，是这些细胞的重要特征。即使克隆诱导和长期未分化扩增后，这种能力仍能持续维持，从而促进摄取。

此外，这些细胞能够表现高水平的碱性磷酸酶（一种主要转录因子）和端粒酶。已发现这些因素对于维持细胞内的多功能至关重要。

此外，hESC 可以轻易分化为神经元、神经细胞、少突胶质细胞和星状细胞。上述特征对于研究神经发生早期发生的事件序列很有用。

然而，使用来自可行胚胎的干细胞充满了伦理问题，因此科学家正在探索其他方法来创建ESC。其他方法包括诱导胚胎生殖细胞、来自死亡胚胎的干细胞以及其他技术。

人类胚胎干细胞市场报告亮点

  • 到2023年，再生医学将以61.1%的份额主导市场。再生医学在治疗多种疾病方面取得了重大进展。此外，源自人类胚胎的多功能细胞已成为生物医学研究的焦点。
  • 干细胞生物学研究领域预计在预测期内复合年增长率最快，达到 11.4%。一些生物製药公司过去已经探索了干细胞生物学的潜力。
  • 在强大的研究基础设施机构和设施的支持下，北美的人类胚胎干细胞将在 2023 年占据市场主导地位。慢性病和遗传疾病的增加对基因治疗产生了巨大的需求。
  • 亚太地区人类胚胎干细胞市场预计在预测期内将显着成长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章人类胚胎干细胞市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 人类胚胎干细胞市场分析工具
    • 波特的分析
    • PESTEL分析

第四章 人类胚胎干细胞市场：应用估算与趋势分析

  • 细分仪表板
  • 人类胚胎干细胞市场：2023 年和 2030 年应用变化分析
  • 再生医学
  • 干细胞生物学研究
  • 组织工程
  • 毒性试验

第五章 人类胚胎干细胞市场：区域估计与趋势分析

  • 2023 年及 2030 年人类胚胎干细胞市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第六章 竞争状况

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Thermo Fisher Scientific, Inc.
    • STEMCELL Technologies
    • Merck KGaA
    • CellGenix GmbH
    • PromoCell GmbH
    • Takara Bio
    • Lonza
    • Cellartis AB
    • ATCC
    • AcceGen
    • Cell Applications, Inc.
    • Bio-Techne
简介目录
Product Code: GVR-1-68038-394-2

Human Embryonic Stem Cells Market Growth & Trends:

The global human embryonic stem cells market size is expected to reach USD 4.08 billion by 2030, registering to grow at a CAGR of 10.5% from 2024 to 2030 according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.

Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.

In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.

Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.

However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.

Human Embryonic Stem Cells Market Report Highlights:

  • Regenerative medicines dominated the market with a share of 61.1% in 2023. Regenerative medicines offer significant advancements in treating several diseases. Moreover, pluripotent cells originating from human embryos have been central to biomedical research.
  • The stem cell biology research segment is expected to witness the fastest CAGR of 11.4% over the forecast period. Several biopharmaceutical companies have explored the potency of stem cell biology in the past.
  • North America human embryonic stem cells dominated the market in 2023 owing to robust research infrastructure institutions and facilities. The rise in chronic diseases and genetic disorders has created a huge demand for gene therapies.
  • Asia Pacific human embryonic stem cell market is anticipated to witness significant growth in the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Human Embryonic Stem Cells Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Human Embryonic Stem Cells Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Human Embryonic Stem Cells Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Regenerative Medicine
    • 4.3.1. Regenerative Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Stem Cell Biology Research
    • 4.4.1. Stem Cell Biology Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tissue Engineering
    • 4.5.1. Tissue Engineering Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Toxicology Testing
    • 4.6.1. Toxicology Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Human Embryonic Stem Cells Market: Regional Estimates & Trend Analysis

  • 5.1. Human Embryonic Stem Cells Market Share, By Region, 2023 & 2030 (USD Million)
  • 5.2. North America
    • 5.2.1. North America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. U.S. Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Canada Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.4. Mexico
      • 5.2.4.1. Mexico Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. UK Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Germany Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. France Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.5. Italy
      • 5.3.5.1. Italy Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.6. Spain
      • 5.3.6.1. Spain Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.7. Denmark
      • 5.3.7.1. Denmark Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.8. Sweden
      • 5.3.8.1. Sweden Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.9. Norway
      • 5.3.9.1. Norway Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. China
      • 5.4.2.1. China Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Japan Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. India Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. South Korea
      • 5.4.5.1. South Korea Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Australia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East and Africa
    • 5.6.1. Middle East and Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Saudi Arabia
      • 5.6.2.1. Saudi Arabia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. UAE
      • 5.6.3.1. UAE Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. South Africa
      • 5.6.4.1. South Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis by Key Market Participants
  • 6.2. Company Categorization
  • 6.3. Company Heat Map Analysis
  • 6.4. Company Profiles
    • 6.4.1. Thermo Fisher Scientific, Inc.
      • 6.4.1.1. Participant's Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Recent Developments/ Strategic Initiatives
    • 6.4.2. STEMCELL Technologies
      • 6.4.2.1. Participant's Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Recent Developments/ Strategic Initiatives
    • 6.4.3. Merck KGaA
      • 6.4.3.1. Participant's Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Recent Developments/ Strategic Initiatives
    • 6.4.4. CellGenix GmbH
      • 6.4.4.1. Participant's Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Recent Developments/ Strategic Initiatives
    • 6.4.5. PromoCell GmbH
      • 6.4.5.1. Participant's Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Recent Developments/ Strategic Initiatives
    • 6.4.6. Takara Bio
      • 6.4.6.1. Participant's Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Recent Developments/ Strategic Initiatives
    • 6.4.7. Lonza
      • 6.4.7.1. Participant's Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Recent Developments/ Strategic Initiatives
    • 6.4.8. Cellartis AB
      • 6.4.8.1. Participant's Overview
      • 6.4.8.2. Financial Performance
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Recent Developments/ Strategic Initiatives
    • 6.4.9. ATCC
      • 6.4.9.1. Participant's Overview
      • 6.4.9.2. Financial Performance
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Recent Developments/ Strategic Initiatives
    • 6.4.10. AcceGen
      • 6.4.10.1. Participant's Overview
      • 6.4.10.2. Financial Performance
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Recent Developments/ Strategic Initiatives
    • 6.4.11. Cell Applications, Inc.
      • 6.4.11.1. Participant's Overview
      • 6.4.11.2. Financial Performance
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Recent Developments/ Strategic Initiatives
    • 6.4.12. Bio-Techne
      • 6.4.12.1. Participant's Overview
      • 6.4.12.2. Financial Performance
      • 6.4.12.3. Product Benchmarking
      • 6.4.12.4. Recent Developments/ Strategic Initiatives